Skip to main content

Table 1 Clinical and demographic characteristics at enrollment (N = 52)

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Characteristic

All patients

First-line treatment

Second-line treatment

 

Number (%)

Number (%)

Number (%)

  

30 (57.7)

22 (42.3)

Median age (range), years

60 (32-70)

60 (32-70)

60 (26-68)

ECOG score

0

20 (38.5)

10 (33.3)

10 (45.5)

1

32 (61.5)

20 (67.7)

12 (54.5)

Sex

Male

32 (61.5)

18 (60.0)

14 (63.6)

Female

20 (38.5)

12 (40.0)

8 (36.4)

Primary lesion site

Colon

32 (61.5)

16 (53.3)

16 (72.7)

Rectum

20 (38.5)

14 (46.7)

6 (27.3)

Positive history of diabetes

9 (17.3)

5 (16.7)

4 (18.2)

Primary tumor resection

46 (88.5)

26 (86.7)

20 (90.9)

Site of metastasis

Liver

31 (59.6)

16 (53.3)

15 (68.2)

Lung

18 (34.6)

13 (43.3)

5 (22.7)

Abdominal cavity

18 (34.6)

8 (26.7)

10 (45.5)

Number of metastatic lesions

Single

24 (46.2)

15 (50.0)

9 (40.9)

Multiple

28 (53.8)

15 (50.0)

13 (59.1)

  1. ECOG: Eastern Cooperative Oncology Group.